News

New Treatment Approved for Certain Glioma Patients On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors […] June 28, 2022

Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […] May 7, 2021

National Brain Tumor Society Congratulates President-elect Joe Biden National Brain Tumor Society (NBTS) offers our congratulations to President-elect Joe Biden and Vice President-elect Kamala Harris. President-elect Biden, more so than any other president in U.S. history, personally understands the devastating nature of brain tumors following the loss of his son, Beau, to glioblastoma. He and his wife, Dr. Jill Biden, care deeply about […] November 10, 2020

Sights & Sounds: Glioblastoma Awareness Day (#GBMDay) 2020 Perhaps Dr. Ned Sharpless, Director of the National Cancer Institute, summed up Glioblastoma (GBM) Awareness Day 2020 best when he said during NBTS’s Defeating GBM: A Virtual Town Hall event, “Events like this are really important to re-energize the community so we can join together and make progress in a disease that where progress has been […] July 23, 2020

Can Newly Approved “Tissue Agnostic” Drugs Benefit Pediatric High-grade Glioma Patients? Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […] September 16, 2019